

## An Overview of Various Cancer Treatments of Melanoma and its Diagnosis

**Received:** 22 October 2022, **Revised:** 14 November 2022, **Accepted:** 26 December 2022

**Mohamed Ishaq.H1, Hariprasath.S1, Lavanya.K1, Divya.B1, Mahalaksmi B1, Nandhini J\***

1 Saveetha College Of Pharmacy, Saveetha Institute of Medical And Technical Sciences, SIMATS, Thandalam, Chennai, India.

### Corresponding Author: Nandhini J,

Lecturer, Dept of pharmaceutics, Saveetha College Of Pharmacy, Saveetha Institute of Medical And Technical Sciences, SIMATS, Thandalam, Chennai, India. E-mail id: jnpnandhini@gmail.com

### Keywords:

Malignancy, Chemotherapy, Mortality, Radiation, Melanoma, Decarbazine, Metastasis, Immunotherapy.

### Abstract

Exposure to harmful radiation, chemicals or genetic factors result in various types of cancers formation and development. Melanoma is one of the dangerous skin cancers. If its not diagnosed early and kept not treated at the right time it can even lead to the death. The direct effect of this skin cancer melanoma is on the melanin pigment producing melanocytes which can be a result of exposure to the Ultraviolet rays and time after time the melanocytes becomes cancerous. Nowadays in the current cancer treatments there are so many possibilities to reduce the spreading of skin cancer cells if they diagnosed earlier. Some of the cancer treatments such as chemotherapy result in many side effects and eventually has the beneficial pharmacological effects on the cancerous cells. Effective treatment and therapies of melanoma involves the chemotherapy, immunotherapy, targeted therapy with combination of transduction inhibitors, regional and systematic chemotherapies, radiation and palliative therapies and final effective removal of cancerous cells by surgery. Immuno-regulatory gates are induced by the human body to spontaneously suppress immune reactions and prevent the immune system from damaging normal cells. Tumor cells can't able to block the immune system when checkpoint blockers are used. Even so, but the survival rate of those affected population is still low and the main reason of the occurrence of this skin cancer is still unclear. This article reviews an overview of diagnosis, pathophysiology and various cancer treatment used in present days and its impact on the melanoma.

### 1. Introduction

Melanoma is one of the life threatening skin cancer. The main impact of this cancer is on the melanin pigment producing cells, the melanocytes. One of the rare growth of the melanoma is inside the throat and nose.<sup>[1]</sup> Analysing many data of impact of this skin cancer, the probability and risk of getting this type of serious skin cancer is increased in the people who were around under the age of 45 and many scientific research concluded that most importantly in women it is most seen this occurrence of this serious skin cancer.<sup>[2]</sup> The most accurate reason and cause of getting this type of skin cancer is still unclear. But, the main cause of all types of cancers especially the skin cancer is the exposure to the harmful rays from the sunlight will increase the risk

and probability of getting this melanoma. But, there are so many effective treatments and therapies are developed and available for melanoma.<sup>[3]</sup> It is important to diagnose early and if its detected early then this skin cancer can be treated and cured successfully. There are several causing factors behind the occurring of this type of skin cancer such as the having the family history of melanomas and development of multiple number of moles in the adults. In some cases the genetic disorders such as the xeroderma pigmentation (XP) also induces the mutation leading cancerous cells.<sup>[5]</sup> Based on the situation getting worse the patients of melanoma classified in the principles and phases of clinical trials varied stages such as stage 0, I, II, III, IV and commonly used diagnosis method in the early

stages is the ABCDEF criteria which is the Asymmetry, Border irregularity, Colour variegation, Evolution of the navi and funny looking, in which the comparison of navi takes place by comparing the patients navi to the normal one.<sup>[6]</sup> Based on the stages of melanoma the treatment is recommended to the patients such as in

stages 0,I initially the surgery is done to remove the cancerous cells and stage II, it can be treated by surgery and immunotherapy and stage III, IV can be treated by treatments such as Immunotherapy, Surgery, Chemotherapy, Radiation therapy, Targeted therapy.<sup>[7]</sup>



The comprehension of the etiology of melanoma has benefited, contributing to targeted therapeutics that have improved the outcomes of disease treatment: Immunotherapies, which would include monoclonal antibodies that target mitogen-activated protein kinase (MEK) inhibitors, v-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene, Programmed Death-1 ligand 1 (PD-L1) and Cytotoxic T-lymphocyte-Associated Antigen-4 (CTLA-4) sometimes don't work and eventually lead to resistance. This emphasises how crucial it is to understand the molecular mechanisms metastasis is the process by which an immobile melanoma cell transforms into a motile cell that can successfully infiltrate distant tissues, preventing immunological destruction; deregulation of cellular energetics. An Image showing the skin cancer melanoma on the skin.<sup>[8]</sup>

When tumour-promoting oncogenes are reactivated or tumour-suppressor genes are silenced by somatic mutations, these pathogenic alterations frequently result.<sup>[9]</sup> Gene expression that would be dysregulated due to epigenetic modifications, including rearrangements (delete, amplify). Early on in the development of malignant transformation, mutations in the genes for B-Raf protooncogene, serine/threonine kinase, NRAS protooncogene GTPase as well as the KIT protooncogene, receptor tyrosine kinase and the loss of transcription factors phosphorylation and tensin locus on

chromosome will occur.<sup>[10]</sup> Figure 1: shows the melanoma skin.


## 2. Pathophysiology

The distinguishing characteristic of melanin producing cells is the generation of melanin. Melanin, on the other hand, possesses a mix of pro-oxidant and anti-oxidant qualities. Its transformation from an antioxidant to a pro-oxidant agent under the impact of many causative variables The crucial and first patho-genetic event that triggers formation of cancer cells is one of several factors, including UV radiation, heavy metals, herbicides. The mutations cause increased stimulation of numerous cell signalling pathways, which in turn causes unchecked cell type-specific proliferation.<sup>[6-12]</sup> The melanocyte's DNA molecule is damaged as a result of the pro-oxidant activity of melanin, which raises the amounts of intracellular oxygen radicals. The main etiological factors are cumulative sun damage, clinical and pathological traits of the precursor lesions, and the genetic aberrations that accompany their development are all taken into account in the most recent generalised classification of the pathways for the genesis of cutaneous, mucosal, and uveal melanomas presented by the WHO. Because all or the majority of these routes refer to nodular cutaneous melanoma, it holds a special place in this categorization. There are eight paths, and they are


# Journal of Coastal Life Medicine

split into two main categories, that correspond to the remaining skin and mucosal melanomas. The first group comprises of three pathways: I, II, and

III and includes melanomas linked to Cumulative Sun-Damage (CSD).<sup>[8-13]</sup>



**Figure 1:** A flowchart showing pathogenesis of melanoma through abnormal growth factor secretion



**Figure 2:** A flow chart explains the pathogenesis of melanoma carcinogenesis through various causes.











The carcinogenesis pathway explains the pathogenesis and pathophysiology of the melanoma. Melanocytes, brain tissue, testicles, and hematopoietic cells all have high levels of the serine/threonine kinase BRAF, which is directly triggered by Rat Sarcoma (RAS) and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) Pathways has been discovered to phosphorylate, which in turn activates MEK (a kinase component of the MAPK pathway), which in turn stimulates Extracellular signal-regulated kinase (ERK) through phosphorylation, hence promoting development and transformation. A melanomas aetiology depends on this pathway. The majority (around 75%) of BRAF gene mutations occur when thymidine is converted to adenine. The protein molecules kinase domain is activated as a response of the valine being replaced by glutamate (V600E) as a functions the mutagenesis which further leads to carcinogenesis.<sup>[9-14]</sup>

### 3. Diagnosis

Timely identification drastically reduces the mortality rate of malignant melanoma itself. The presumptive diagnosis for melanoma is largely decided by the severity of the tumour, which is a major consideration that unceasingly gets worse over time.<sup>[11]</sup> In point of fact, relevant and important cases among the extracted feature, melanoma identification, and management continue to be significant in the medical assessment of the illness. Malignant melanoma has always had the favorable position of being found on the skin, enabling non-invasive correct identification, in particular with respect the majority of other nations.<sup>[12]</sup> However, pathological examination persists to be the gold standard for diagnosis. examining one's own skin.<sup>[13]</sup> Skin self-examination has a tremendous opportunity as a quick and simple way to evaluate for melanoma and premalignant. Melanomas were universally recognized prior to the scheduled 1980s through distinguishing clinically macroscopic qualities; they were known to occur when they seemed enormous, distended, and formation of fungus similar disorientation.<sup>[14]</sup> Melanoma primary prevention increasingly ascending to the forefront of the agenda for sustainable development.<sup>[15]</sup> It is very hard to agree with approaches to ensure the sensitivity of tissue self-

assessment.<sup>[16]</sup> Determining lesions with that of the greatest chance just being melanoma thorough inspection. In order to educate medical professionals and the public in general what to do to recognize melanoma in its early clinical manifestation, the "ABCD" guidelines have been developed in 19's. The characters in the acronym ABCD Configurations stand for asymmetry, border irregularity, colour variegation, and diameter longer than 6 mm. It was then updated to "Evolving," which is crucial for understanding segmental melanomas.<sup>[17]</sup> The members of the public and new dermatologists may employ this guidelines to quickly and straightforwardly discriminate respectively commonplace moles and dermatological lesions that are significantly prone to be prematurely melanoma.<sup>[18]</sup> They were not being supposed to function as a complete guideline for recognizing all melanomas because when a "solid medical vision" has always been needed to analyse the condition. When considering the ABCDE principles, the self-skin assessment proneness varies from 58% to 91%.<sup>[19]</sup> According to the dissection, non-invasive imaging technologies should be employed and the assessment after the screening need to be more reliable because many investigators were integrating fluorescence into IHC, phylogenetic analysis hybridization, sequence analysis, mass spectrometry (MS), and IHC.<sup>[20]</sup> Enhanced cancer cell surface area rough approximations, the elimination of mitotic index as little more than a justification for trying to stage a narrow melanoma, the development of spread to nearby lymph node (N) subgroups depending on the percentage of optimistic nearby lymph nodes, the development of the metastasis (M) groupings depends on the location of lymph vascular invasion, and increasingly broad stage arrangements in stage III ailment to effectively help distinguish lengthy outcomes in patients are a few of the meaningful clear evidence modifications already represented in present system.<sup>[21]</sup> The American Joint Committee on Cancer Staging System can also be used by pathologists and medical professionals as little more than a base for exposition and grading. The result of contemporary technological improvements in skin cancer prediction is the adoption of non-invasive imaging techniques, including the creation of non-invasive imaging methods to analyse melanoma.<sup>[22]</sup>

**Table 1:** Shows the ABCDE criteria of early diagnosis of melanoma

Normal	ABCDE Criteria	Cancerous
	<p><b>“A” is for Asymmetry</b></p> <p>If you draw the line through the middle of the mole, the halves of a melanoma won't match in size.</p>	
	<p><b>“B” is for Border</b></p> <p>The edges of an early melanoma tend to be uneven, crusty or notched.</p>	
	<p><b>“C” is for Colour</b></p> <p>Normal moles are uniform in colour, A variety of colours, especially white or blue is bad.</p>	
	<p><b>“D” is for Diameter</b></p> <p>Melanoma usually larger in diameter than a eraser of pencils and although they may be smaller.</p>	
	<p><b>“E” is for evolving</b></p> <p>When a mole changes in physical properties or begins to bleed or scab, this points to danger</p>	

Throughout fact, numerous cell phone implementations, particularly MoleScope,

UMSkinCheck, and SkinVision, have already been established with both the expressed objectives of

# Journal of Coastal Life Medicine

promoting patient rapid identification, contacting a bigger audience, and undertaking cost-effective and efficient examinations.<sup>[23]</sup> But repeated studies has also shown that those methods mainly deliver misleading data. Melanocytic indicators do, nevertheless, possess shortcomings, like the feature because these colour every melanocytes which makes them ineffective to discriminate between melanoma and then a innocuous melanocytic expansion.<sup>[24]</sup> Besides that, if so many delicate identifiers haven't been used, some melanoma types (particularly pathologic changes melanomas) are missing the proper development and among specific particular melanocytic biomarkers, that would lead to either a falsified identification.. Retrospective case-control studies provide the bulk of the evidence for the correlation between melanoma development with some component of excessive sunlight exposure and ultraviolet (UV) light. Virtually majority of the information establishing the relationship among both melanoma progression and perhaps minor aspect of prolonged daylight including ultraviolet (UV) light comes from observational literature reviews. Thus a view is well substantiated by an overabundance of circumstantial data. As seems to be the case with plenty of some malignancies, a thorough experimentally induced prototype that demonstrates the sunlight aetiology for melanoma is absent. Parallel to the above, there's not many enough relevant in vitro study results. This different assumption are generally supported by north of the equator research findings, population diversity, the disease xeroderma pigmentosum, demonstrable predisposition designs, movement of people and "essential timeframe" scholarly articles, and interrogations of skin facility relocation, gastrointestinal and furthermore the optional extra

body parts malignant melanoma, but instead cytologic neuroblastoma.<sup>[25]</sup>

## 4. Systematic Treatment

Relying upon that unique attributes of the cancer, the therapeutic interventions comprise physically clearance of the cancer cells, chemotherapeutic approach, radiotherapy, including photodynamic therapeutic approach. Treatment with specific agents, PDT, or immunotherapy.<sup>[26]</sup> Melanoma individuals having stages I to IIIB usually receive surgery as their maintenance therapy. In accordance with the pharmacological and disease causing characteristics of the cancer, surgical procedures change. In situ melanomas have a maximum load of 0.5 cm, cancers cells up to 2 cm dense have a maximum load of 1, and cancer cells over 2 mm have a maximum load of 2. 11 The use of supplementary drugs is advised to raise survival, such as targeted therapy and immunotherapy.<sup>[27]</sup> Mastectomy is the conventional therapeutic approach who have a solitary melanoma spreading, when in many cases chemotherapy also even be assigned. Potential treatment strategies were already identified as the consequence of investigation into the genetics of melanin producing cells and indeed the revelation that biological mechanisms implicated inside this pathophysiology of something like the evolution of tumours in melanin producing cells. The European Society for Medical Oncology treatment guidelines for cutaneous melanoma demonstrate a high level of an information from reliable sources for defining the cancer phase. A modification screening is actually required sometimes in cancers.<sup>[28]</sup> The stages of melanoma and its diagnosis and treatment is explained in table 2.

Melanoma Stages	Stage Description	Treatment
Stage 0	This initial stage of melanoma points out the melanoma skin cancer cells identified in the skin external or outside layer	Surgery

# Journal of Coastal Life Medicine

Stage I	The initial melanomas are thin and solely identified in the skin which reveals an formation of ulcer like in microscope to pathologist and this stage is further divided into IA and IIB and here no lymph nodes disseminated. [thickness-less than 1mm]	Surgery
Stage II	This stage is advanced than stage- I in which even deeper penetrates into the inner thick skin layer of skin and its even thicker than 1mm with ulceration. And further this stage also divided into A,B,C categories in taking the account of the thickness of cancerous cells	Surgery, Immunotherapy
Stage III	And here melanoma is further thick like 2mm but not more greater than 4mm. in this stage we can recognise some local spread of the melanoma or in interference to lymphatic system examined.	Immunotherapy, Surgery, Chemotherapy, Radiation therapy, Targeted therapy.
Stage IV	This is a critical stage which explains that melanoma has entered to the bloodstream and near body parts. GI and lungs even brain also affected. And this stage is really hard to prevent as it already transferred to body parts	Immunotherapy, Surgery, Chemotherapy, Radiation therapy.

**Table 2:** Shows the description and treatment of various stages of melanoma

## 5. Chemotherapy

Recognizing that surgical management is unlikely to remain beneficial to those experiencing aggressive sickness, medication is the subsequent safeguard. Individuals would've had no additional therapeutic strategies till around previously. Melanoma has now disseminated must have been treated with chemotherapeutic approaches.<sup>[29]</sup>

Melphalan, also described as 1-phenylalanine mustard, became a beneficial drug utilised on initial chemotherapeutic approaches clinical testing against metastatic melanoma in 1968, nevertheless and many problems arise, it seemed inefficient and extremely poisonous. The FDA subsequently permitted the use of dacarbazine, which became the initial and sole chemotherapy for melanoma. Owing to those modern clinical breakthroughs,

# Journal of Coastal Life Medicine

health expectancy of people suffering metastatic melanoma is significantly improved, and chemotherapeutic brought minimum utilisation and relatively further management such as the targeted medicines and immunotherapies are employed in further they are consistently utilised.<sup>[30]</sup> To achieve maximum functional recovery, beginning of the melanoma and it's identification indicated crucial. The effective constituent of dacarbazine's orally small molecule, TMZ, was utilized to manage metastatic melanoma. Despite none variations overall OS or quantitative clinical outcomes, TMZ showed significantly declining baseline of the PFS when matched against dacarbazine.<sup>[31]</sup>

Chemotherapeutic approaches emerged as the first melanoma treatment method used. Chemotherapeutic modifications were already optimized to evaluate therapeutic efficacy, although overall survival (OS) remained unchanged. Barriers toward programmed cell death are almost certainly the primary causes of chemotherapy chemoresistance with melanoma. Notwithstanding becoming reinforced differently by different therapies, chemotherapeutic approaches remains essential in the palliative development of severe, progressing, and recurring

malignant cancer cells.<sup>[32]</sup> Combining medications that impair the cancer cell across several ways can improve the effectiveness of the treatment. Numerous medications need to be injected right into a vein. This method of chemotherapy is known as intravenous or IV. Employing drugs which it harm the tumor cells in diverse situations will make your therapy more successful. Many drugs require being directly administered into something like a vein. Intravenous, or IV, chemotherapy would this be type of treatment. The length of something like the session can range from about a moments to many hrs. Numerous IV drugs function better whenever administered over a few hours.<sup>[33]</sup> You administer them by wearing or carrying somewhat nozzle. This would be chemotherapeutic approaches administered via continuous intravenous infusion. External chemotherapeutic approaches has administered by the consumption of solid and liquid dosage formulation. Their dispensary may involve selecting up your doctor's recommendation but rather utilize something at work in the result.<sup>[34]</sup> A syringe shots typically given whenever chemotherapeutic medications is injected intravenously. The treatment can sometimes be given intramuscularly or even as a subcutaneous chemotherapeutic administration into an artery.

Chemotherapy agents	Mechanism of action	Examples	Type of cancer treated	Side effects
Antimetabolites	Through replacing both typical RiboNucleic Acid and DeoxyRiboNucleic-Acid, the basic producing blocks, these medicines prevent the production of DeoxyRiboNucleic-Acid or RiboNucleic Acid.	5-fluorouracil  6-mercaptopurine  Cladribine Floxuridine Hydroxyurea	Leukemia, breast Cancer ovarian cancer, intestinal tract cancer and other cancers	1.long-term damage to the bone marrow may sometimes lead to acute leukemia 2. Cytotoxicity may lead to hair loss, fatigue, memory and eating challenge , nausea pain sterility 3.Recurrence 4. Drug resistance



# Journal of Coastal Life Medicine

		Pentostatin Thioguanine		
Alkylating agent	Damage DNA directly phases of the cell cycle	Mechlorethamine,  Chlorambucil, Cyclophosphamide,  Streptozocin, carmustine,  Decarbazine,  Ethyleneimines:thiotepa  Altretamine	Lymphoma,  Leukemia, Multiple myeloma, Sarcoma, melanoma and ovarian cancer.	1.Cytotoxicity may lead to hair loss, fatigue, memory and eating challenge , nausea pain sterility 2.Recurrence 3.Drug resistance
Anti-tumor  Antibiotics	Several medications function all throughout cell cycle & prevent an enzyme responsible for DeoxyRiboNucleic Acid replication from doing its job.	Daunorubin,  Doxorubicin, Epirubicin, Actinomycin-D, Adriamycin	Used for variety of cancers	High doses causes permanent damage to the heart.

**Table 4:** shows the major chemotherapy drugs and their mechanism and side effects

For some skin cancer cells chemotherapeutic approaching medications is injected right through into abdomen but rather peritoneum.<sup>[35]</sup> Medications may be further administered intravenously. This type of therapy works effectively for peritoneal cancers. Often, chemotherapeutic approaches given for something like a specific duration, including six months or a year. You could also put up with chemotherapeutic approaches for increased duration because it works. Numerous against tumours drugs feature adverse

actions that are too serious to be taken on a regular basis. Physicians often offer us all interruptions from these medications that allow patients can rest and recover before your following session. Like a consequence, these normal cells regenerate. Chemotherapy may be employed to cure patients as the primary alone or method. Chemotherapy is sometimes used to eradicate any malignant cells that may have been present following earlier therapies, including such resection.<sup>[36]</sup>

## 6. Immunotherapy

Immunotherapy is one of the effective and sophisticated type of treatment of cancer. To boost the immune system and help the body find and get rid of tumor cells, it uses substances created mostly by body or developed in the lab. Immunotherapy could be used to treatment for a variety of cancer types. It could be utilised either independently or in combination with certain other therapeutic strategies like chemotherapy. This article also gives you the basics of how immunotherapy treats cancer. The immune system is a highly developed system that your body employs to fight cancer and t his method involves proteins, organs, and cells.<sup>[37]</sup> Tumours frequently defeats the immune system’s natural defences, which promotes the proliferation and dissemination of tumour cells. In order to boost your immune system, some monoclonal antibodies disrupt or prevent immunological checkpoints. Immunological checkpoints are used by the body system to immediately puts an end to the immune reactions and prevent the immune system to kill normal cells. Tumour cells have the ability to trigger these checkpoints to aid in immune system evasion. Checkpoint inhibitors prevent tumor cells from inhibiting the immune system.<sup>[38]</sup> As checkpoints, such inhibitors commonly interfere

with the PD-1/PD-L1 and CTLA-4 routes. Several checkpoint inhibitors have been given the go-ahead by the U.S. Food and Drug Administration for use in various cancers. Moreover, there are two checkpoint inhibitors which are used to cure tumours elsewhere in the body if they have specific genetic abnormalities. This type of therapy is referred to as “tumor-agnostic therapy”. Cancer immuno-editing is a technique wherein several immune system components aid the cancer cells in eluding the hosts or protect the hosts from either the development of early tumours.<sup>[39]</sup>

Whether it be by modifying the cancer cells immunogenicity or by reducing the immune system’s response to the tumour. The mechanism is rigorously controlled with aid of immune checkpoints, and these are immunological cell surface receptors that control whichever the initiation or reduction of immune stimulation. On however one hand, triggering the immune system is necessary to stop the tumourigenesis, although it is ultimately leads to autoimmune diseases. The emerging field of monoclonal antibodies opposing suppressing immune checkpoints ctla-4 and PD-1 have resulted in significant anticancer outcomes by increased expression immune initiation at various phases from the immunological cycle.<sup>[40]</sup>

**Table 4:** A list of immunotherapy drugs of cancer treatment and its targets

Type	Drug	Company	Target
Immunomodulatory drugs Targetting immune cells	Ipilimumab	Bristol-Myers Squibb	CTLA-4
	Nivolumab	Bristol-Myers Squibb	PD-1
	Pembrolizumab	MSD	PD-1
	Atezolizumab	Roche/Genentech	PD-L1
	Avelumab	Pfizer/Merck	PD-L1
	Durvalumab	AstraZeneca	PD-L1
Other immunomodulatory	Aldileukin	Novartis	IL2R
	Imiquimod	VRX	ITLR7
	aInterferon	Sumitomo Dainippon	IFNAR1;IFNAR2
	aInterferon-1b	Pharma,	IFNAR1
	aInterferon-2a	Shenzhen Kexing Biology	IFNAR1;IFNAR2
	aInterferon-2b	Cadila Healthcare	IFNAR1;IFNAR2
	BInterferon	MSD	IFNAR1
	y-Interferon-1b	TORAY Otsuka Pharmaceutical	IFNAR1

# Journal of Coastal Life Medicine

Cancer vaccine	BGG Live ImmuCyst Immuno BCG Mycidac-C Sipuleucel-T TICE BCG Uro-BCG GARDASIL Cervarix	Shire Plc Sanofi Ataulpho Paiva Cadila Healthcare Dendreon MSD Merck MSD GlaxoSmithKlinre	TLR TLR TLR TLR2 Autologous cell vaccine TLR TLR HPV HPV
Cell therapy	Tisagenlecleucel Axicabtagene ciloleucel	Novartis GILEAD	CD19 CD19
Oncolytic virus	Oncorine	Sunway Biotech	CD40L

T cells, a type of immune cell, fight infection in the body immune system. During T-cell therapy, blood from the patient is obtained to remove T cells. Then, in a laboratory, the cells are given significant proteins known as receptors. The receptor on these T cells allows them to recognise cancer cells. The altered T cells are returned to the system. Once there, they look for and get rid of cancer cells. This kind of therapy is referred to as chimeric antigen receptor (CAR) T-cell immunotherapy. Several of the negative effects include fever, disorientation, low blood pressure, and, in rare instances, seizures. CAR T-cell treatment can be used to treat some blood cancers.<sup>[41]</sup> Experts are continue looking into this type of treatment as well as other ways to modify T cells to fight cancer cell. Interferon is the designation of the interferon that is most frequently used to cure cancer. Poor prognosis and survival have been connected to high PD-L1 expression on tumour cells in a number of different cancer types, particularly renal cell carcinoma. Ovarian cancer, melanoma, and RCC [42]. High PD-L1 affirmation on tumours was already linked to poor prognosis and mortality inside a variety of cancer forms, including renal cell carcinoma. Melanoma, RCC, and ovarian cancer.<sup>[42]</sup> TILs are found in 98% of PD-L1(+) tumours contrasted to 28% of PD-L1(0) tumours, suggesting a correlation between its activity of PD-L1 and the prevalence of TILs in individual melanocytic lesions. Pembrolizumab, an IgG4/kappa isotype humanised monoclonal antibody, blocks the interaction for both PD-1 and PD-L1 and PD-L2 by attaching to PD-1. It was initially studied at three separate doses in a

stimulating competing I study (KEYNOTE-001): 1, 3 and 10mg/kg provided during one or two weeks. Notwithstanding positive results with ICIs, pancreatic cancer patients who receive single-agent PD1 inhibitors have a goal number of respondents that varies between basically non-existent to microsatellite stable.<sup>[43]</sup> Colonic adenocarcinoma does have a 15%–30% life expectancy, whereas melanoma, Hodgkin lymphoma, cutaneous squamous cell cancer, and Merkel cell cancer have 55%–85% life expectancies. Even if there is a noticeably significant possibility with toxicity, the addition of just an anti-CTLA4 medication increases the number of respondents.<sup>[44]</sup> An important development in the immunology and oncology combined field was made possible by a better understanding of the pivotal role played by the cancer micro-environment in the regulation of anti-cancer immune surveillance. Yet another greater connection exists between an immunologically relevant responsiveness to ICIS treatment and immune cell migration through into cancer cells micro surrounding conditions.<sup>[45]</sup>

## 7. Targeted Therapy and Biomarker Testing

Different targeted medications were developed to address specific underlying molecular issues which is characterised and identified in skin cancer melanoma. Far more potential among them are dabigatran and vemurafenib, both BRAF inhibitors. Rafenib, that was approved by the FDA of metastatic and unremarkable BRAF-mutated melanoma, respectively, in 2011 and 2013. Whereas roughly 60% of individuals having BRAF

# Journal of Coastal Life Medicine

mutant melanomas respond strongly to various therapies, the proportion concerning about the affected people eventually develop secondary tolerance.<sup>[46]</sup> To seek to accomplish an even more long-lasting action and researching people developing pharmaceutical medications and innovative pharmaceutical drug combinations, and a number of the pathways that lead to this secondary resistance generates around 100,101 reports. Predicting which patients will respond out of a

given medication as well as which ones won't is crucial to avoid adverse side effects and expensive cost of treatment.<sup>[47]</sup> The development of predictive biomarkers is an essential topic. Examples of biomarkers that've been studied include exosome sequencing studies, gene expression profiles, and T cell expression patterns in the tumour microenvironment. The usefulness among these biomarkers is the focus of countless investigations.<sup>[48]</sup>

**Table 5:** A list of various targetted drug therapy used in cancer treatment.

Drug	Tumour	Target	Detection method
Trastuzumab	Metastatic colorectal cancer	HER2	IHC, FISH, ISH
Cetuximab	Gastric cancer	EGFR	IHC, FISH
Imatinib Mesylate (Gleevec)	CML, GIST with activated c-kit receptor tyrosine	Bcr/abl	IHC
Bevacizumab	Bcr/abl.	VEGF	IHC
Gefitinib (Iressa)	kinase, other sarcomas	Mutant EGFR	Mutational analysis, immu-noblotting
Erlotinib (Tarveca)	Colorectal cancer	Antiapoptotic bcl-2	Immunophenotyping
Rapamycin	Non-small-cell lung cancer	Mutant EGFR	by IHC
RAD001	G3139 (Genta, Berkley)	m-TOR	Mutational analysis, immu-noblotting
BAY43-9006	Hematologic malignancies and malignant	RAF-kinase	ELISA
BMS354825	mela-Antiapoptotic gene	Kit	Mutational analysis
Lapatinib	bcl-2	EGFR ,cKit	
Sunitinib	Non-small-cell lung cancer	HER2	
Pertuzumab	Breast, prostate, renal cancer,	Bcr/abl	
Dasatinib	Melanoma	PDGFFR	

Finding genes, proteins, and other elements (sometimes referred to as tumour markers or biomarkers) that can provide information about cancer can be done by doing a biomarker test. The use of biomarker testing can help you and your doctor decide on an anticancer therapy. In the beginning stage of active metabolite cancer therapy, the drug-inducing enzyme and its tumors environment are targeted. The non-toxic prodrug, which serves as the supporting enzyme for the exogenous enzyme that is targeted and produced in tumours, is then given systemically.<sup>[49]</sup> Three approaches can be utilised to selectively activate prodrugs in tumour tissues by exogenous enzymes: gene-directed enzyme prodrug therapy, virus-directed enzyme prodrug therapy, and antibody-directed enzyme prodrug therapy. The main component of prodrug cancer therapy is the

delivery of drug-inducing enzyme or the building blocks of genetics or inheritance or function performing agents. Protein is administered to the tumour tissues, followed by a systemic prodrug.<sup>[50]</sup> The targets of the starting initial generation of class I pan-PI3K inhibitors were PI3K, PI3Ka, PI3Kb, and PI3KY. Wortmannin and LY294002 had little action and in current studies, new pan-PI3K inhibitors with improved pharmacokinetic properties are being explored, and Target specificity They mostly have cytostatic anti-cancer effects. New medications that target both PI3K and mTOR may have increased anticancer activity.<sup>[51]</sup> With efficacy against PI3K, PI3Ka, PI3Kb, and PI3Ky, BAY 80-6946 is a pan-class I PI3K inhibitor. A stage I trial found that BAY 80-6946's MTD was 0.8 mg/kg intravenously once a week. Negative impacts including increased level of

glucose, weakness and exhaustion, vomiting sensation, diarrhoea, and inflammation of the mucous. Therapeutic efficacy was seen in affected people with critical gastric problems, endometrial, and breast tumors.<sup>[52]</sup>

## 8. Radiation Therapy

Radiation is used as a direct agent to eliminate malignant cells. The radiation used is referred to as radioactive materials since this produces ions (electrically charged particles) and accumulates power inside tissue cells it flows across. This accumulated energy has the power to kill tumor cells or damage them by changing their own inherited traits. Deoxyribonucleic acid gets damaged which is caused by high-energy radiation hinders subsequent cell growth and proliferation. Radiation damages equally healthy and cancerous cells, but the main goal of treatment is to expose abnormal tumor cells to more radiation whereas sparing healthy cells nearby or in the path of something like the radiation.<sup>[53]</sup> Radiation can be used as a highly effective palliative treatment to lessen patients' cancer-related discomfort in addition to being provided with the intention of treating the disease. In addition to other treatments including surgery, chemotherapy, or immunotherapy, radiation therapy may also be employed. Prior to surgery, radiation therapy, also known as "new-adjuvant treatment", tries to shrink the tumour. Any microscopic tumor cells that might have survived surgery can be destroyed by radiation. It is well known that various malignancies behave to radiation therapy in different ways. Radiation therapy delivered in a splintered schedule is employed, with different radiobiological features of different normal tissues and malignancy being taken into account. Platinum-containing drugs like cisplatin and carboplatin, alkylating drugs like mitomycin C, and temozolomide are some of the chemotherapeutic treatments that have been most successfully repurposed for concurrent chemo-radiotherapy.<sup>[54]</sup> Topotecan and other topoisomerase poisons, which are radiation inducers, are also researched. It is unclear why increased radiation justifies increased total Damage to DNA. Alkylating medications may only produce instantaneous, strongest action in physiological radiation field, but some other action such changing the regeneration of tumor

tissues and stifling faraway micro metastases, might make chemo-radiation greater efficient than radiation alone in addressing a variety of disorders. The advantages of chemotherapy and radiation therapy combined with alkylating medications could well be offset by increased normal tissue injury. Three related PIKK enzymes, DNA-PK, ATR, and ATM, have roles in early DNA methylation that overlap.<sup>[55]</sup>

## 9. Surgery

Stage IV melanoma these have typically considered associated with poor predictions, with nothing more than a typical one-year recovery of around 30%. Patients in especially those suffer from distance the prognosis for metastases is poor. Surgery, radiation therapy, and systemically medications are used to manage elderly patients. To treat metastatic melanoma, however, systematic drug therapy has frequently been ineffective.<sup>[56]</sup> Only one chemotherapy drugs have shown success versus melanoma with overall reaction percentages of 10-25% and an average overall survival (OS) of 7-12 months, however full recoveries are unusual. According to a meta-analysis of 50 trials, the improvement from some of the numerous chemotherapy and bio-chemotherapy combinations is roughly 4.2%, with both a mean OS of 5 months. Despite the substantial gains offered through these apply best practices drugs, surgery for stage IV melanoma continues to be an important approach to therapy that has the potential to effectively manage the condition instantaneously and successfully cure restricted disease.<sup>[57]</sup> There are numerous explanations why stage IV melanoma must be treated with surgical resection as soon as possible. Although studies have indicated that 30% of stage IV affected people (M1a through M1c inclusive) are eligible following partial ablation, surgery is still the most important strategy to manage single malignancies. The medical procedure does indeed have a tolerable further negative consequences and number of survivors associated and is linked to good survival rates. In cases of metastatic melanoma, which are various indicators of surgical success.<sup>[58]</sup> It was further supported by the finding suggesting surgery is an important element of the treatment for metastatic melanoma. Tumoral aggregates that are challenging to manage to treat systemic therapy individually may be more

easily removed through surgery when paired using cutting-edge immuno-oncology and targeted medications.<sup>[59]</sup> Specific clinical outcomes and the health of the individual in fact, surgery ought to be performed wherever feasible to decrease the goal of following adjuvant health care assistance. A sample again from biopsy is being sent to the pathologist, who could really examine it and calculate the Breslow thickness to validate the melanoma diagnosis. The area required for performing a comprehensive regional removal is determined by the Breslow thickness. Whenever a large localized excise is performed, the excised tissue ought to be at the position of something like the quadriceps femoris fascia and there seems to be already no evidence to support the claim that eliminating any underneath fascia results inside a better result.<sup>[60]</sup>

## 10. Conclusion

Melanoma is one of the dangerous skin cancers which require a early diagnosis and treatment to treat and prevent it. By far the causes is identified from the patient symptoms and signs of malignancy which further reveals an research data that the causes of this cancer is still unclear and researchers are still finding the exact reason. And chemotherapy, immunotherapy, targeted therapy with combination of transduction inhibitors, regional, radiation and palliative therapies and final effective removal of cancerous cells by surgery are the some of the current treatment which can help the patient to overcome and reduce the symptoms and spreading by damaging the cancerous cells specially the chemotherapy, it has more potential as well as side effects and still used. And radiation therapy also used to destroy cancerous cells. The immunotherapy also an important treatment of cancer which supports our immune system to turn against cancerous cells. But the mortality is still low in patients as it requires proper diagnosis and treatment. Furthermore, the preceding informations in this article explains the various melanoma treatments, pathophysiology and diagnosis.

## References

- [1] Siegal R, Miller KD, Jemal A. Cancer statistics, 2012. *Ca Cancer J Clin*. 2014 Jan;64(1):9-29.
- [2] Isola AL, Eddy K, Chen S. Biology, therapy and implications of tumor exosomes in the progression of melanoma. *Cancers*. 2016 Dec 9;8(12):110.
- [3] Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho E. Epidemiology of melanoma. *Exon Publications*. 2017 Nov 30:3-22.
- [4] White LP. Studies on melanoma: sex and survival in human melanoma. *New England Journal of Medicine*. 1959 Apr 16;260(16):789-97.
- [5] Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Edwards MJ, Chagpar AB. Gender-related differences in outcome for melanoma patients. *Annals of surgery*. 2006 May;243(5):693.
- [6] Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. *In vivo*. 2014 Nov 1;28(6):1005-11.
- [7] Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. *Journal of the American Academy of Dermatology*. 1987 Sep 1;17(3):459-68.
- [8] Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature*. 2016 Jun;534(7605):47-54.
- [9] Aversa J, Song M, Shimazu T, Inoue M, Charvat H, Yamaji T, Sawada N, Pfeiffer RM, Karimi P, Dawsey SM, Rabkin CS. Prediagnostic circulating inflammation biomarkers and esophageal squamous cell carcinoma: A case-cohort study in Japan. *International journal of cancer*. 2020 Aug 1;147(3):686-91.
- [10] Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, French Familial Melanoma Study Group, Bénard J, Bressac-de Paillerets B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. *Human molecular genetics*. 1998 Feb 1;7(2):209-16.
- [11] Rebecca VW, Sondak VK, Smalley KS. A brief history of melanoma: from mummies to mutations. *Melanoma research*. 2012 Apr;22(2):114.

# Journal of Coastal Life Medicine

- [12] Lee C, Collichio F, Ollila D, Moschos S. Historical review of melanoma treatment and outcomes. *Clinics in dermatology*. 2013 Mar 1;31(2):141-7.
- [13] Vickers NJ. Animal communication: when i'm calling you, will you answer too?. *Current biology*. 2017 Jul 24;27(14):R713-5.
- [14] Mehnert JM, Kluger HM. Driver mutations in melanoma: lessons learned from bench-to bedside studies. *Current oncology reports*. 2012 Oct;14(5):449-57.
- [15] Li C, Hu Z, Liu Z, Wang LE, Strom SS, Gershenwald JE, Lee JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. *Cancer Epidemiology Biomarkers & Prevention*. 2006 Dec;15(12):2526-32.
- [16] Read J, Wadt KA, Hayward NK. Melanoma genetics. *Journal of medical genetics*. 2016 Jan 1;53(1):1-4.
- [17] Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D. TERT promoter mutations in familial and sporadic melanoma. *Science*. 2013 Feb 22;339(6122):959-61.
- [18] Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *New England Journal of Medicine*. 2011 Jun 30;364(26):2507-16.
- [19] Collins B, LeonBarnes Jr E, Abernethy J. Oral malignant melanoma. *J Clin Oncol*. 2005;55:74-108.
- [20] Schwämmle V, Sidoli S, Ruminowicz C, Wu X, Lee CF, Helin K, Jensen ON. Systems level analysis of histone H3 post-translational modifications (PTMs) reveals features of PTM crosstalk in chromatin regulation. *Molecular & Cellular Proteomics*. 2016 Aug 1;15(8):2715-29.
- [21] Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial.
- [22] Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E, Rescigno M, Moro G, Ricciardi-Castagnoli P. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. *Nature immunology*. 2001 Sep;2(9):882-8.
- [23] Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon- $\alpha$ 2, interleukin (IL)-2, IL-15, IL-21, and IL-12. *In Seminars in oncology 2015 Aug 1 (Vol. 42, No. 4, pp. 539-548)*. WB Saunders.
- [24] Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4<sup>+</sup> CD25<sup>hi</sup> Foxp3<sup>+</sup> regulatory T cells in cancer patients. *Blood*. 2006 Mar 15;107(6):2409-14.
- [25] Refaeli Y, Van Parijs L, London CA, Tschoep J, Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. *Immunity*. 1998 May 1;8(5):615-23.
- [26] Gallagher DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott DF, Atkins MB, Sukhatme VP. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. *Clinical Cancer Research*. 2007 Apr 1;13(7):2115-20.
- [27] Samlowski WE, Kondapaneni M, Tharkar S, McGregor JR, Laubach VE, Salvemini D. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. *Journal of Immunotherapy*. 2011 Jun 1;34(5):419-27.
- [28] McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. *Journal of Clinical Oncology*. 2008 May 1;26(13):2178-85.
- [29] Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. *Journal of clinical oncology*. 1995 Mar;13(3):688-96.

# Journal of Coastal Life Medicine

- [30] Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *Journal of clinical oncology*. 1999 Jul;17(7):2105-.
- [31] Mitchison DA. Basic mechanisms of chemotherapy. *Chest*. 1979 Dec 1;76(6):771-80.
- [32] Services ST, Hospital B. A controlled clinical trial of the role of thiacetazone-containing regimens in the treatment of pulmonary tuberculosis in Singapore: Second report. *Tubercle*. 1974 Dec 1;55(4):251-60.
- [33] Velu S, Andrews RH, Angel JH, Devadatta S, Fox W, Jacob PG, Nair CN, Ramakrishnan CV. Streptomycin plus pyrazinamide in the treatment of patients excreting isoniazid-resistant tubercle bacilli, following previous chemotherapy. *Tubercle*. 1961 Jan 1;42(2):136-47.
- [34] Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. *Bull. Int. Union Tuberc.* 1978;53(1):5-12.
- [35] Dickinson JM, Mitchison DA. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. *Tubercle*. 1970 Dec 1;51(4):389-96.
- [36] Guo N, Minas G, Synowsky SA, Dunne MR, Ahmed H, McShane R, Bhardwaj A, Donlon NE, Lorton C, O'Sullivan J, Reynolds JV. Identification of plasma proteins associated with oesophageal cancer chemotherapeutic treatment outcomes using SWATH-MS. *Journal of Proteomics*. 2022 Aug 30;266:104684.
- [37] Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. *Thrombosis research*. 2006 Jan 1;118(5):555-68.
- [38] Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for recurrent cervical cancer. *Cancer treatment reviews*. 2008 Nov 1;34(7):603-13.
- [39] Cao H, Phan H, Yang LX. Improved chemotherapy for hepatocellular carcinoma. *Anticancer research*. 2012 Apr 1;32(4):1379-86.
- [40] Laviano A, Rossi Fanelli F. Toxicity in chemotherapy—when less is more. *New England Journal of Medicine*. 2012 Jun 14;366(24):2319-20.
- [41] Achkar T, Tarhini AA. The use of immunotherapy in the treatment of melanoma. *Journal of hematology & oncology*. 2017 Dec;10(1):1-9.
- [42] Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. *Annals of Pharmacotherapy*. 2015 Aug;49(8):907-37.
- [43] Morrissey KM, Yuraszek TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. *Clinical and translational science*. 2016 Apr;9(2):89.
- [44] Esfahani K, Roudaia L, Buhlaiga NA, Del Rincon SV, Papneja N, Miller WH. A review of cancer immunotherapy: from the past, to the present, to the future. *Current Oncology*. 2020 Apr;27(s2):87-97.
- [45] Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ. Next generation of immunotherapy for melanoma. *Journal of Clinical Oncology*. 2008 Jul 10;26(20):3445-55.
- [46] Beiu C, Giurcaneanu C, Grumezescu AM, Holban AM, Popa LG, Mihai MM. Nanosystems for improved targeted therapies in melanoma. *Journal of clinical medicine*. 2020 Jan 23;9(2):318.
- [47] Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. *Nature*. 2007 Feb;445(7130):851-7.
- [48] Czarnecka AM, Bartnik E, Fiedorowicz M, Rutkowski P. Targeted therapy in melanoma and mechanisms of resistance. *International Journal of Molecular Sciences*. 2020 Jun 27;21(13):4576.
- [49] Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. *The oncologist*. 2011 Jan;16(1):5-24.



# Journal of Coastal Life Medicine

- [50] Queirolo P, Acquati M. Targeted therapies in melanoma. *Cancer treatment reviews*. 2006 Nov 1;32(7):524-31.
- [51] Khan N, Khan MK, Almas an A, Singh AD, Macklis R. The evolving role of radiation therapy in the management of malignant melanoma. *International Journal of Radiation Oncology\* Biology\* Physics*. 2011 Jul 1;80(3):645-54.
- [52] Barker CA, Postop MA. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. *International Journal of Radiation Oncology\* Biology\* Physics*. 2014 Apr 1;88(5):986-97.
- [53] Finger PT. Radiation therapy for choroidal melanoma. *Survey of ophthalmology*. 1997 Nov 1;42(3):215-32.
- [54] Hong A, Fogarty G. Role of radiation therapy in cutaneous melanoma. *The Cancer Journal*. 2012 Mar 1;18(2):203-7.
- [55] Goldschmidt H, Breneman JC, Breneman DL. Ionizing radiation therapy in dermatology. *Journal of the American Academy of Dermatology*. 1994 Feb 1;30(2):157-82.
- [56] Krausz AE, H William Higgins II, Etkorn J, Sobanko J, Shin T, Giordano C, McMurray SL, Golda N, Maher IA, Leitenberger JJ, Bar A. Systematic review of technical variations for Mohs micrographic surgery for melanoma. *Dermatologic Surgery*. 2021 Dec 1;47(12):1539-44.
- [57] Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, Eggermont AM. Surgery and radiotherapy in the treatment of cutaneous melanoma. *Annals of oncology*. 2009 Aug 1;20:vi22-9.
- [58] Beaulieu D, Fathi R, Srivastava D, Nijhawan RI. Current perspectives on Mohs micrographic surgery for melanoma. *Clinical, Cosmetic and Investigational Dermatology*. 2018;11:309.
- [59] Kaufmann R. Surgical management of primary melanoma: Clinical dermatology• Review article. *Clinical and Experimental Dermatology: Clinical dermatology*. 2000 Nov;25(6):476-81.
- [60] Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. *Current opinion in oncology*. 2004 Mar 1;16(2):155-60.